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Respected Dean, members of the board of the Faculty of Psychology & Neuroscience, 
distinguished colleagues, family, friends and all other listeners. 
 
What a strange title, you must have thought when you first saw this. For me it is very 
logical though and I hope at the end of this talk you will think the same. So for 
everyone in the audience, understanding the title is my intended learning outcome for 
today. Someone asked me: “What is a farewell speech at a University? Do you have 
to keep it academic or is it mostly a victory lap?” My answer was that it may be 
somewhere in between: a very selective academic review of the area I worked in, 
understandable for a broad audience, looking back and looking forward, mixed with 
my memories and an attempt to entertain. 
Let’s kick off with that. These days it is common, if not required, at the start of a 
presentation to declare possible conflicts of interest.  What we then very often see, at 
least at the meetings that I attend, is a long list of companies from whom the speaker 
has received payments in the recent past. Obviously, the longer such a list, the more 
impressive it is perceived to be. But I have almost nothing to declare. Yes I have 
worked in 2 big pharma companies and no doubt I am still influenced by that, but I 
think mainly in terms of that it has broadened my horizon and expanded my scientific 
knowledge, much more than when I would have stayed at University all the time.  
Referring to my past work as a research scientist in big pharma companies, the joke is 
that I have been introduced to students as the Professor who came back from the dark 
side, if that hasn’t just happened already I am doing so now.  
You could also say I have flown out of that golden cage because I don’t care so much 
about bling-bling. 
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But I could have completely different motives and this declaration is to make you 
aware of it. 
 
 
 
What you can expect is the 8 paragraphs as outlined here.  
The most salient aspects of my work will be highlighted, I will take you on a tour 
through some of my past and current experiences, prime interests and fixations. 
 
 
1. My Interests before University 
 
 
Conflicts	of	interest	(COI)	
•  Yes	I	have	worked	in	big	Pharma:	GSK	and	Roche	
•  These	COI	slides	are	always	misused	to	boost	one’s	
ego	.	.	.	.	
•  I	play	in	a	band		(10¢	Trinkets)	and	will	try	to	sell	CD’s	
•  No	I	don’t	have	shares	(anymore)	
•  But	I	came	back	from	the	dark	side	
Content	
1. 	Before	the	beginning	–	a	blast	from	the	past	
	
2. 	The	beginning	–	Institute	for	Drugs,	Safety	&	Behavior	
	
3.  The	background	–	Development	of	New	Medicines		
	
4. 	Top	Down	vs.	Bottom-Up	
	
5.	 	The	middle	–	depression,	some	cheering	up	.	.	.		
	
6.	 	Placebo,	the	best	fake-drug?	
	
7. 	Towards	the	end	–	dementia	
	
8. 	The	end	–	new	researchers,	new	treatments!	
1.	My	interests	before	University	
•  The	Dark	side	of	the	Moon	.	.	.	.	.	.	
What	made	/	makes	me	tick?			J	
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OK, let’s have a blast from the past in an attempt to explain how I got here. When I 
was a teenager, like most in the seventies, I was fascinated by space travel, so each 
time there was a space mission, the family clustered at the radio or TV and listened to 
those sound bites like ‘Houston, we have a problem’. In those days I became also 
fascinated by the music of Pink Floyd, so even before I had ever touched my hands on 
any psychoactive substance I was already of the opinion that this kind of music was 
mind-altering, changing consciousness, like others claim that drugs do, but much 
healthier. Lyrics on the famous Pink Floyd album dark side of the moon refer to 
several themes that occurred later in my scientific career, such as: ‘Luna-tic’, ‘Brain 
damage’ and ‘There's someone in my head but it's not me’. And the book ‘Psychic 
Exploration’ binds this together, it was written by Ed Mitchell, astronaut on Apollo 
14, he was the sixth man on the moon. The concept ‘dark side of the moon’ first got 
public attention when Apollo 8 astronauts were orbiting the moon for the first time, so 
when they were at the dark side, behind the moon, or as it was called officially, at the 
far side of the moon, no radio-communication was possible. Ed Mitchell though, 
claimed he was telepathic and tried to seek telepathic contact with someone on earth 
when Apollo 14 was at the dark side of the moon. He claimed this as important 
existential evidence for paranormal phenomena and that is what Psychic Exploration 
is about. As a teenager I was very intrigued by the concept of paranormal 
communication and I wanted to understand this and develop these skills (perhaps to 
compensate for my poor social skills at the time). That was why I turned to studying 
Psychology. The program in Groningen, quickly cured me of my belief in my 
telepathic skills (it wouldn’t make sense anymore now anyway, because we all have 
mobile phones; only at the dark side of the moon, telepathy would still be an asset).  
 
 
2. Institute for Drugs, Safety & Behavior 
 
 
2.	Institute	for	Drugs,	Safety	&	Behavior	
Drugs	&	Driving	
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However, I landed on a different planet, the Institute for Drugs, Safety & Behavior. 
This picture appeared on the front page of the Maastricht University newspaper the 
Observant in September 1986 and everybody referred to it as “Charlie’s Angels”. Jim 
O’Hanlon founded it, he transferred the research program ‘Drugs & Driving’ from 
Groningen to Maastricht and the first claim of success, is for Jim O’Hanlon, but I’d 
also like to declare my share, is that this research program still exists today within the 
Faculty of Psychology & Neuroscience – the claim of cusses is also for Jan 
Ramaekers who leads it now. And as you may be able to see, the Head of 
Instrumentation of this faculty, Huub Hamers, also started his career there. The focus 
of the drugs and driving program is to discover whether prescribing existing or new 
medicinal drugs pose a danger for activities in daily life such as driving a car in 
traffic. The easiest example is to think of alcohol. After too many drinks no one is 
capable of driving because brain functions, and therefore important cognitive and 
motoric capacities have become insufficient or maladaptive. The same principle can 
be applied to studying behavior under the influence of psychoactive substances, 
mostly reflected by the question: ‘at which dose does influence become apparent and 
how does it relate to the chemical properties of the substance?’ But as said the 
strength of the Drugs & Driving program is that it is focused on the question if a 
certain substance (a medicinal drug, or an illicit drug, or perhaps even a nutrient) has 
safety related side effects in a very important daily life activity and if so, above what 
dose. Thinking back of this, my best memory is the speed and the dedication with 
which we started. The instrumental car had to be built-up with measurement devices 
and a computer. But first it had to be collected at the Volvo garage. It was and still is 
the only time in my life I picked up a brand new car at a garage, so at the time I had 
no script for the moment the garage manager asked me to sign it onto my name. I 
thought that can’t be right, because my insurance won’t cover this, it should be on the 
name of the University. So I called my boss Jim O’Hanlon and asked who was to sign 
this? It should have been the head of the university’s facility services, but it was 
Holiday time, Friday afternoon and Jim told me, ‘just put it on your name and bring it 
here’, ‘we urgently need to start building it up’. So I obeyed and I got the instant 
bonus: 2 bottles of wine from the Volvo garage!  
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3. Development of new Medicines 
 
The study of side effects was a good start so I went on for the real thing: investigating 
therapeutic effects of medicinal drugs and ultimately the question how do you develop 
new medicines. As you can see here the drug discovery and development pipeline is a 
rather long process with several stages and the ones with the red arrows are where I 
have been working in.  
Limiting it to disorders of brain function, this is about finding new medicinal drugs 
and testing them under strictly controlled conditions according to the highest 
scientific standards. In this way empirical data are collected showing evidence that 
novel compounds work for neurological indications like dementia, parkinsons disease, 
multiple sclerosis, migraine and so forth. And likewise for psychiatric indications like 
depression, schizophrenia, autism, ADHD, and so forth. Basically, all brain diseases 
that can be targeted biologically.  
Zooming out you can see that the so-called neuroscience drugs, medicines for 
neurological and psychiatric diseases, have comprised about 20% of all new 
medicines over the past 25 years. And to be more specific, we are talking about on 
average 7 new neurological and 4 psychiatric medicinal drugs per year over the past 
25 years. 
 
 
But when we look in more detail at these past 25 years we can see that there were still 
relatively many new psychiatry drugs in the 1990s and early 2000, but at present, the 
last 4 years, no new drugs have been registered in psychiatry. Only neurology drugs 
were registered recently. For example 2 new drugs were ocrelizumab for multiple 
sclerosis in 2017 and erenumab for migraine in 2018. Both are so-called biologicals 
Discovery	~7yrs	 Development	~8yrs	
Registration	
Drug	/	Diagnostic	
to	Market	
Drug	Discovery	Research	
preclinical,	in	test	tubes	then	in	animals	
Search	for	
Brain	Targets	
Biomarkers	
Clinical	Drug	Research	&	Development	
In	humans;	healthy	volunteers	then	patients	
3.	Development	of	New	Medicines	
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rather than small molecule drugs, they are antibodies. These are really new in class 
medicines with a different mode of action than their precedents and much more 
efficacious as well. But also because these are a new class of medicines they were 
approved, but with the requirement that for several years safety data need to be 
systematically collected and evaluated.  
 
 
4. The Anatomy of Bottom-up and Top-Down 
 
 
 
Now for something completely different. When we talk about the science of how 
drugs, substances influence human behavior, we always talk about 
psychopharmacology, but there are actually 2 different ways we can study this. The 
most dominant mode of thinking about this is that the properties of the substance such 
as the dose and the duration of action and also whether it is able to enter the brain 
predict its effects on experience, feeling the drug, and behavior. And these factors we 
call the Pharmacology of the drug. And when it concerns brain effects we call it 
Psychopharmacoloy. But actually this is wrong. We should call it 
Pharmacopsychology.  
Because the important assumptions concern the causality. A drug is ingested 
absorbed, distributed via the bloodstream to the brain where it binds to certain 
neurotransmitter receptors, and from there neurophysiological processes are changed 
and psychological effects can be observed. Therefore the word Pharmaco Psychology. 
From Cause to Effect; Bottom Up, or from simple to complex. 
4.	The	Anatomy	of	Bottom-Up	and	Top-Down	
Psycho-
pharmacology	
Pharmaco-
Psychology	
Top-down:	from	mind	to	brain	to	cell	
	
	or:	from	mind	to	chemistry		
Bottom-up:	from	cell	to	brain	to	mind	
	
	or:	from	chemistry	to	mind	
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We need to realize though that the true meaning of Psychopharmacology is the 
science of how mind, or thoughts, or behavioural intentions affects the chemistry of 
the brain, so here the causality is opposite. Think about how we often in daily life use 
expressions such as “I felt the adrenaline running through my veins” to express some 
form of excitement. Of course you don’t feel that – even though it may be true –, at 
best you can feel heart pumping and sweating, well, those would be the biomarkers. 
But we assume that the commands for these biomarkers come from above, from the 
brain. Therefore cause effect is Top Down, from complex thought to lower level 
physiological processes. 
And how is this relevant for drugs. I like to quote a study (Rush et al, 2001) that 
focused on how drug naïve human volunteers experience or feel drug effects. Healthy 
volunteers received different doses of amphetamine, methylphenidate – known as 
Ritalin – and placebo. Amphetamine and methylphenidate are both stimulant drugs, if 
anything, they increase heart rate and breathing rate, they generally increase mobility 
and talking. These subjects were asked to rate if the drug that they had taken was a 
sedative/downer, a stimulant/upper, or placebo. The most striking result is that 75% of 
healthy volunteers rated d-amphetamine and methylphenidate as sedative/downer and 
25% as stimulant/upper; none thought it was placebo. Placebo was identified as a 
“placebo/blank” (63%) or “sedative/downer” (37%); none thought it was a stimulant. 
Drug effects are most commonly misinterpreted in drug-naïve young men. There is an 
Age effect: experiencing drug effects is a Learning process. There is also a Gender 
Effect: Females are better at interpreting drug effects, probably because they are 
better at interpreting their own bodily signals? This experiment makes you wonder if 
the drug effect is determined by the drug (bottom-up) or by the brain: in terms of what 
the subject expects (top-down). So who obeys? And to make another leap: in early 
drug development, we work a lot with asking subjects what they feel, either by 
interview or by rating scales, so here is an area for improvement: they should be 
trained into drug connoisseurs first. 
 
 
5. Depression 
 
Strangely, there are no common references to neurotransmitters about depressed 
mood, such as I felt low on serotonin, or I felt too low or too high on glutamate. More 
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common is to say, I feel the blues, I feel sad, or I feel gloomy, so purely behavioral 
descriptions. And when this goes on too long, we call it major depression. But 
scientists have searched for a biological basis of the concept of depression for very 
long. In this scheme you can see in the development over the years that we went from 
the monoamine theory of depression – that is indeed assuming low on adrenalin and 
low on serotonin is causing depressed mood – leading to the first antidepressant drugs 
in the 1960s to one that focused specifically on serotonin, leading to the SSRIs in the 
late 1980s where we actually still are now, in terms of registered drugs. But as you 
can see there are still 2 unresolved problems, which is the high number of refractory 
patients, many say 40% of patients is actually the maximum number that benefit from 
these drugs. And the next problem is the latency, or the time it takes before a 
therapeutic effect will manifest. The latest hypothesis is that of a glutamatergic 
mechanism, like we know is present in ketamine, is capable of delivering immediate 
antidepressant effects. Presently there is one candidate new antidepressant drug, 
esketamine, an intranasal formulation of a powerful anesthetic called ketamine, better 
known in party circles as “special K”, very close to approval by the FDA.  
This is after 50 years of failed biological hypotheses about major depression (for 
example antagonists of neurokinins, corticotropins, metabotropic-glutamate receptors 
all failed). The real problem is that we cannot measure depression, at least not its 
biological construct, we still have no biomarker of depression, so the serotonin 
hypothesis of depression is very questionable. And because we don’t have a 
depression biomarker, Adam Cohen from the Centre for Human Drug Research in 
Leiden in his farewell speech last year said: “Personalised medicine in Depression is 
like Having a suit fitted by a blind tailor”.   
 
 
5.	Depression	
•  Personalised	medicine	in	
Depression	is	like	having	a	
suit	fitted	by	a	blind	tailor	
(Cohen,	2018)	
MDD = Major Depressive Disorder 
ADP = Antidepressant 
MAOI’s, TCAs = antidepressant drugs from the 1950s -  1960s 
SSRI = Specific Serotonin Reuptake Inhibitor       
 (Fluvoxamine®, Prozac®, Seroxat®, Cipramil®) 
2019: improved ADP (S-ketamine) reaches the market? 
Pereira	&	Hiroaki-Sato	(2018)		
Acta	Neuropsychiatr	30:	307-22 
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But having said that, manipulations of serotonin definitely have measurable effects, 
both in animal and human subjects. Mechanistic studies all show that SSRIs have 
immediate effects mediated by the brain, for example on pupil size, on cortisol, on 
facial emotion recognition and memory. Yet the patients do not immediately feel 
better on it. Initially they often feel severe side effects, like nausea and gastric 
discomfort.  
So what does an SSRI do on behavior? Most salient effect: increasing social 
dominance. And it has been demonstrated to do so already after the first dose. Simon 
Young writes: “Increasing serotonin decreases quarrelsome behaviours and enhances 
agreeable behaviours in humans. Antidepressants act in part by effects on social 
behaviour, which leads to a gradual improvement in mood. Positive social responses 
of interaction partners triggers a cycle of positive social behavior, and this iterative 
process leads to clinically significant improvement in mood.”  (Young et al, 2014). 
A combination of aggressive and affiliative behaviors is important for achieving 
social dominance. Facial emotion expression of social partners plays a key role in 
achieving dominance status. SSRIs enhance reward sensitivity to the facial emotions 
of social partners (Tse et al., 2014) and that is the key mechanism.  
For example, when you have a colony of monkeys there is a social hierarchy, the most 
dominant, or the alfa monkey is number one and has the least stress. Not the lowest in 
rank, but typically the number 2 and the number 3’s are the most stressed. So if you 
give number 3 an SSRI it climbs in rank to become number 2.  
So one obvious paradox is: if all are taking SSRIs nobody benefits. And also: in 
humans these effects may be more covert and more subtle. 
Because this may all be very abstract, let’s consider a case from real life. Well, from a 
real newspaper, the Volkskrant Saturday magazine with the weekly sent-in letter by a 
reader, with a problem and then the question what would you do? Along with the 
selected responses a week later. When I read this one, I thought it may actually 
illustrate an antidepressant effect in real life, because what the message reflects in my 
opinion is the shift in social rank, that is positively evaluated by the patient, but is not 
always appreciated by others in the life of the patient. As such, I thought this was a 
perfect example of the consequence in daily life of the effect of an SSRI, at least if it 
was indeed an SSRI. Because the letter didn’t say what the drug and the dose was. 
And I have to confess to you that I very often thought that these so-called reader 
letters are constructed. So I thought I am just going to ask the editors whether they 
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know the name of the drug and the dose or if they can still ask. In this case, the 
threshold is low because my stepsister works at the editorial board of this newspaper, 
so I asked her the question. It’s a big newspaper of course and this was not her 
department, so she forwarded the question for me and to both our surprise we got a 
relatively quick and very detailed answer and the permission to share it in this 
presentation.  
 
 
 
To put it short, the answer was paroxetine 20 mg once daily. It is indeed an SSRI, 
whether this can be considered a low dose is a matter of debate, but at least it fitted 
perfectly well with behavioral changes that I thought you can expect after an SSRI. 
The patient also wrote back in response to my question, that by now, he is more 
stabilized on the medication and his wife has adapted to his new and improved 
persona and actually appreciates it more. Finally, this also made clear to me that these 
letters are real, they are not fake!  
 
 
 
Social	dominance	effect	of	SSRI	as	
reflected	by	this	readers’	letter	in	large	
dutch	newspaper:	
	
“I	have	suffered	depressed	mood	for	
years.	Since	last	year,	I’m	on	a	low	
maintenance-dose	antidepressant1,	
which	has	made	me	feel	alive	again.	
Since	this,	my	wife	thinks	I	sometimes	
behave	‘over	the	top’	and	this	annoys	
her.	Should	I	listen	to	my	wife	and	stop	
my	medicine	use	with	the	chance	that	I	
will	return	into	the	sad,	quiet	and	
withdrawn	old	boy?”		
	
Man	(68),		
name	known	to	the	editors.	
	
De Volkskrant 12 january 2019 
1	paroxetine	20	mg	
Psychedelics	
•  Albert	Hoffmann	(Sandoz)	
cycling	through	the	
streets	of	Basel	on	an	
accidental	dose	of	
LSD	.	.	.	.	(19	april	1943)	
•  Microdoses	of	
psychedelic	drugs	are	
now	under	investigation	
as	novel	antidepressant	
drugs		
Rucker	et	al	(2018)	
Neuropharmacol.	142:	200-18	
Heal	et	al	(2018)	
Neuropharmacol.	142:	1-6	
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Now let’s turn to the next era of antidepressants perhaps: psychedelics. Yes indeed, 
this is about LSD, psilocybin and related substances. In the last table you saw that 
attention in antidepressant drug development had moved from serotonergic drugs to 
glutamatergic drugs like esketamine. In psychedelics, both serotonergic and 
glutamatergic mechanisms are active and like ketamine they have an immediate effect 
on mood. They were banned after 1967 mainly because of their so-called 
hallucinogenic or pro-psychotic side effects. But during the last 10 years, scientific 
interest in the mechanisms of action in these drugs has revived. Recent trials with 
psychedelics in major depression, mainly with psilocybin, show initial evidence of 
safety and efficacy, so this is very promising, only the regulatory and legal hurdles to 
licensing psychedelics as medicines remain high.  
It might be possible to tailor these substances in such a way that the potentially 
therapeutic mechanisms that induce the positive effects on mood are maintained and 
the psychotic side effects are engineered out, firstly by looking at lower dose levels. 
The near future will have to tell us whether this is effective.  
When I lived in Basel, I cycled a lot, but I never knew about this annual cycling day 
to celebrate the discovery of LSD.  
But it is a typical example of the paraphernalia that can be associated with certain 
drug effects. As I said in the beginning, music can have this effect very strongly too 
and many popsongs are associated with this, but there is one that cannot be unheard 
when considering psychedelic drug effects. So here is where we get high with a little 
help from my friends. One moment for tuning and some mind-altering music will be 
administered to you. 
 
-- singing --   
 
For those who don’t know it: This was White Rabbit by Jefferson Airplane 
The author, Grace Slick, singer of Jefferson Airplane, was strongly influenced by 
fantasy stories that were read to her as a child, such as Alice in Wonderland. She said 
White Rabbit stands for following your curiosity and for not always obeying others. 
And I think that is an essential role example for scientists. One other line from the 
song refers to placebo: the ones that mother gives you, don’t do anything at all. In 
addition, she actually gives some sound methodological advice for drug researchers: 
one pill makes you larger and one pill makes you small. That could be taken as: you 
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have an investigational drug and an active comparator or reference drug, against 
which you would like to make the new drug look better or bigger and another 
reference - placebo - that doesn’t do anything at all. Or it could also mean 2 doses of 
an investigational drug versus placebo.  
 
 
6. Placebo 
 
One other way to get to placebo, but also to get cycling back in this story is the 
clinical trial on the effects of Erythropoietin, or EPO, on cycling by the Centre for 
Human Drug Research in Leiden. What I like about this study in particular is that 
where everybody, and I have to admit including me, believes that it is absolutely 
beyond any doubt that taking EPO gives cyclists an unfair advantage, there was 
actually no empirical evidence from any controlled scientific experiment or trial, with 
adequate placebo and blinding.  
Highly competitive amateur cyclists received EPO or placebo and performed several 
tests on physiological functions and ergometers and a real over the road cycling event, 
up the Mont Ventoux. And what they found even surprised me, they wrote that 
although the well-known effects of EPO on hematological and physiological 
parameters were indeed observed, that is: more red blood cells and more oxygen 
uptake after EPO relative to placebo, this did not translate to better cycling 
performance either in the laboratory or on the road.  
 
 
 
6.	Placebo	 •  in	Latin:	I	shall	please	
•  It’s	fake	medicine	!	
Heuberger	et	al	(2017)	Lancet	
Haematol.		4:	e374-86	
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I take this example because even though it is not strictly neuroscience, it is the most 
stunning example of a placebo-effect and the powerful influence of expectation about 
drug effects in the individual taking them. It is typical that this scientific fact is 
completely discarded by the professional cycling world. They just don’t believe the 
data. The only thing I could say is that, it would need a replication, and I herewith 
volunteer for participating in it. It is also interesting that this is a typical example of a 
drug effect that gets lost in translation. What I mean with that is that the mechanistic 
effect can be demonstrated in the laboratory, the increase of red blod cells and 
hematocrit values as well as the increase in oxygen uptake by EPO, but it doesn’t 
translate to better performance.  
 
 
7. Dementia; Drugs and/or lifestyle 
 
OK, that was the uphill battle, now let’s look at the downhill struggle. This graph is a 
very typical simplified representation of the gradual decline of cognitive functioning 
over the years in patients with mild to moderate alzheimers disease and how it is 
influenced by the only category of registered medicinal treatment to date. As you can 
see the blip in the graph may give 1-2 years extra but it doesn’t stop the process. 
That’s why this drug is called symptomatic. And to introduce another case example: 
during the nineties I worked in the memory clinic under the supervision of Jelle Jolles 
and Frans Verhey, working on several clinical trials investigating potential new 
Alzheimer medicines. Looking back now, these were all symptomatics and we never 
saw any effects. Yet, when the moment to use one was there, in 2008, it was my 
mother, then aged 89, who was in the process of typical Alzheimers Disease and I 
couldn’t resist initiating that we asked her doctor to prescribe an anticholinesterase 
inhibitor, because I had the feeling she was the perfect patient. No comorbidities and 
still motivated to perform cognitive activities like reading the newspaper out loud. To 
make a long story short we saw that blip, perhaps even a little bit bigger than as 
shown here in the graph. So it gave approximately 2 years extra in the period where 
somewhat normal communication was still possible. So it worked much better than I 
expected. It didn’t cure my mother - she died last year at age 99 - but at least I saw 
some of my knowledge and years long research justified. 
 14 
But what we really need is a disease modifier, a drug that prevents or stops the 
underlying disease that causes Alzheimers Dementia. In the next slide I will show 
there are still many candidate drugs for that, but we still haven’t found what we are 
looking for. 
 
 
 
For that reason it is just as important to work on the so-called life style factors that 
may prevent the onset or decelerate the process of alzheimers disease. In short: Learn, 
Move, Eat healthy. Credits to the colleagues of the memory clinic who set up the 
project: “We are the medicine ourselves”. I totally believe in it, I definitely am very 
good at the first two, and struggling with the third one. Yet, my memory isn’t as good 
as when I was 20.  
What you see here are many dots and each represents one drug that could have a 
therapeutic effect in Alzheimers Disease, but these effects have yet to be clinically 
demonstrated. On the left symptomatics, on top the biological disease modifiers, on 
the right the small molecule disease modifiers. Red dots are targeted on amyloid 
plaques, blue dots are targeted at tau. But although there are many candidate drugs, no 
new drug has really been registered since the nineties and not a single disease 
modifier has got to the finish line yet. Optimism about the possibility to cure 
Alzheimers Disease by removing or preventing amyloid plaques has diminished to 
near zero after more than 25 years of drug development. But I thought I absolutely 
don’t want to leave you with no hope, so I very selectively singled out one very 
surprising new drug candidate, COR388 it has just got into Phase 1. 
 
7.	Dementia;	Drugs	and/or	lifestyle?	
	•  Medicinal	Drugs	
-  symptomatic	
Functional	decline	(MMSE	score)	in	Alzheimers	
Disease	in	years	before	and	after	symptomatic	
treatment	
Phase	IV	data	
cholinesterase	
inhibitors	
	
n=2460		from	
Electronic	Health	
Records	
•  Lifestyle	
-  learn,	move,	
eat	healthy	
-  disease	modifyer	?	
Perera	et	al	(2014)	
PlosOne	9:	e109484 
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This is basically an antibacterial that is aimed at so-called gingipains, and these are 
bacteria known for causing periodontitis, they have been found in the brains of 
Alzheimer patients and are associated with formation of amyloid plaques and tau. An 
association of Alzheimers disease with periodontitis has also been demonstrated. 
Therefore another important lifestyle factor in the prevention of Alzheimers Disease 
may have been identified: dental hygiene. So maybe the lifestyle factors can be 
extended to: “Learn, Move, Eat Healthy and Always brush your teeth”. But it is for 
the next generation of drug developers to bring this forward, we shall see. 
 
 
8. Drug Development and Neurohealth 
 
 
 
And speaking of the next generation of drug developers, what I worked on in the past 
5 years was setting up the research master drug development and neurohealth or DN. 
Here you see the landmarks that summarize its conception. 
Newest	alzheimer	drug	
candidate:	COR388	
Porphyromonas	gingivalis	
keystone	pathogen	in	chronic	
periodontitis:	gingipain	
	
Found	in	Alzheimer’s	disease	
brains:	amounts	correlated	with	
tau	and	ubiquitin	pathology	
	
COR388	is	small	molecule	
antibacterial	
	
Mechanism:	Gingipain	inhibition	à		
	
	bacterial	brain	infection	ê,		
	Aβ	1–42	productionê	
	Neuroinflammation	ê,		
	neurons	in	hippocampus	é 
 
	
Lifestyle	co-factor:	dental	hygiene	!	
	
	
Cummings	et	al	(2018)	Alzheimers	
Dement	(N	Y);	4:	195–214	
 
Dominy	et	al.	(2019)	
Sci.	Adv.	5	:	eaau3333	
 
COR388	
8.	Drug	Development	and	Neurohealth	
	•  2004:	start	FPN	research	master		
-  cognitive	&	clinical	neuroscience	
-  track	‘psychopharmacology’?	✖	
•  2013:	FPN	Limburg	agenda	
-  ‘drug	discovery	&	development’	
•  2014:	group	of	staff	from	FPN	and	FHML	formed	
-  ‘drug	development	&	neurohealth’	
•  2015:	approved	by	faculty	&	university	board		✔	
•  2016:	start	first	group	of	14	students	✔	
•  2018:	graduation	first	group	of	students	✔	
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Already during the start of the research master cognitive & clinical neuroscience, we 
talked about a track ‘psychopharmacology’ but at that time the idea wasn’t mature 
enough. 
I found documents from 2013 on where a track ‘drug discovery & development’ was 
mentioned and let’s say from there on DN was built. 
 
 
 
DN is built around the so-called drug discovery and development pipeline, as a 
perspective to learn the underlying science and view it in that light. All the core 
courses are at some point related to a stage in the drug discovery and development 
pipeline. 
 
 
 
I thankfully use this staff slide that I also used in the so-called student recruitment 
pitches to illustrate the multidisciplinary character of the program. It is taught by 
different groups form 2 faculties and again from left to right it can be projected onto 
the early and late stages in drug discovery and development. And Thanks means here 
Discovery	~7yrs	 Development	~8yrs	
Registration	
Drug	to	Market	
Discovery	Research	–	preclinical,	in	test	tubes	
then	animals	Brain	Target	
Clinical	Research	&	Development	
In	humans;	healthy	volunteers	then	patients	
Courses	aligned	to	drug	research	&	development	pipeline	
Core Courses Practicals    Workshops Parallel Courses 
Safety & Drug Metabolism Target Discovery Clinical Development 
Psychiatric Neuroscience 
Project management    Valorisation 
Robot-based high-throughput screening       In silico Drug Discovery       Western Blotting        Neuroanatomy    
Advanced Statistics I and II,    SPSS,   LISREL,   Colloquia,   Scientific Writing,   Grant Writing,   Electives  
Introduction to: Molecular & Biochemical Techniques  /  Psychology 
Big Data in Drug Discovery Animal Models Electrophysiology Biomedical Brain Imaging 
Applied Therapeutics Drug Discovery Neuropsychopharmacology 
Pharmacoepidemiology 
Genetics 
RMa Cognitive and Clinical Neuroscience 
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Thanks	to	Staff	from	different	Faculties	&	Departments	
RMa Cognitive and Clinical Neuroscience 
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I start thanking everybody. Thanks to all colleagues who have contributed to the 
genesis and the actual carrying out of drug development and neurohealth. 
 
 
 
Thanks also to the students, or should I say they should thank me? In any case I really 
enjoyed teaching the first 2 groups of DN students but I think the picture tells it all. 
 
 
 
I also want to thank all my colleagues in Neuropsychopharmacology and 
Psychopharmacology, especially those in Psychopharmacology and more specifically 
Anke Sambeth, Arjan Blokland, Eef Theunissen, Jan Ramaekers, Jos Prickaerts and 
Kim Kuypers. Because they treated me, amongst many things, on a railway cycling 
trip in the mountains in Belgium. I also want to thank Rudy Schreiber that he was 
willing to leave Boston for Maastricht and take over my role, so that I am reassured 
that DN is in good hands. What you see here by the way is valorization, or value 
creation, of colleauguial appreciation, there are only a few of these mugs and 
Members	of	the	first	group	at	graduation;	2018	
Thanks	to	all	
students	!	
Thanks	to	all	colleagues	in	NP	and	PP	!	
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probably their value has gone up now. But feel free to use my famous one-liner: 
‘Psychopharmacologists do it double blind’. 
 
 
 
And now for the commercial break: Thanks to my friends from 10 cent Trinkets, Joep 
Muys, Wim van der Zanden, Pim Tabak and Huub Verheijden: drumming with you 
guys has definitely boosted my impact factor. 
 
 
 
Who obeys all the bosses? Well I did, most of the time! I think it is typically me to put 
this in a table, put some numbers with it and run a big data analysis on it. And what 
do we see: they were all male. Well, that’s coincidence. I nevertheless learned a lot 
from all of them. I will not mention them all but there are three here: Jelle Jolles, you 
survived me the longest with 10 years. Jochen Theis, the peculiar aspect of our 
working relation is to put it bluntly that I hired you in GSK and you hired me in 
Roche. Arjan Blokland, you have the honour to be my last boss. . . . What you can see 
is that bosses are much more faithfull in academia. In industry I had a different boss 
	 	 	Thanks	to:	
Joep	Muijs		
Wim	van	der	Zanden	
Pim	Tabak	
Huub	Verheijden	
Thanks	to	all	my	former	bosses:	
84-86	Groningen 	RUG	 	 	Talib	Rothengatter		
86-92	Maastricht	 	UM-FdGW	Jim	O’Hanlon	
92-02	Maastricht	 	UM-FHML	Jelle	Jolles	
02-07	Cambridge		GSK	 	 	John	Brown,	Alan	Bye,		
	 	 	 	 	 	 	 	Emilio	Merlo	Pich,	Ed	Bullmore		
07-12	Basel	 	 	Roche		 	Jochen	Theis,	Luca	Santarelli,	
	 	 	 	 	 	 	 	Gabriel	Vargas,	Paulo	Fontoura	
12-14	Cambridge		CamCog 	Andy	Blackwell	
14-18	Maastricht	 	UM-FPN	 	Arjan	Blokland	
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nearly each year. Of course these are the direct reporting line bosses, there are also 
some on a higher-up level. And guess what?  
They are the female bosses. Professor Anita Jansen the dean of faculty of Psychology 
and Neuroscience and Dr. Carolien Martijn the director of this faculty. Thank you 
very much for your support. 
 
 
 
Finally, Pim Tabak, my dearest, my fairest: you were the real reason that I came back 
from the dark side to Maastricht. 
And so I have said. Ik heb gezegd. 
 
  
Thanks	to	all	higher-up	bosses!	
Thanks	to	the	Dean	and	the	Director	of	the	Faculty	of	
Psychology	and	Neuroscience,	Prof.	Anita	Jansen	and	Dr.	
Carolien	Martijn	
Thanks	to	my	significant	other;	just	as	in	the	sex	
chromosomes	there	is	only	one	letter	different:	Pim	
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